Bristol-Myers Squibb Company (BMY) announced on Wednesday that the FDA has accepted the supplemental New Drug Application for Augtyro also known as repotrectinib, and has given the application Priority Review status and set a Prescription Drug User Fee Act goal date of June 15, 2024. The filing acceptance is supported by data from the Phase 1/2 TRIDENT-1 trial and CARE study, which focused on adult and pediatric patients with NTRK-positive solid tumors, respectively.
The Augtyro drug treats adult and pediatric patients aged 12 and above with solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.